Moderna has announced that the US Food and Drug Administration (FDA) will consider approving its new flu vaccine after the public controversy is resolved.[1][5] This dispute blocked the company's request for the first injection of its kind.[1] The announcement came on Wednesday, about a week after the previous events.[1] The FDA previously refused to review the application because it considered Moderna's 40,000-person clinical trial inadequate.[5] The study compared the new vaccine with the regular flu vaccine and found it to be slightly more effective in adults 50 and older.[5] The FDA criticized the choice of a comparator vaccine for people over 65, although it initially approved the study.[5] The mRNA-1083 vaccine is a combination vaccine against influenza and COVID-19, but does not yet have final approval.[1][2][3] Approval may be delayed until 2026 due to additional data requirements.[2][3]